Literature DB >> 21542745

The hemostatic system as a modulator of atherosclerosis.

Julian Ilcheff Borissoff1, Henri M H Spronk, Hugo ten Cate.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21542745     DOI： 10.1056/NEJMra1011670

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  136 in total

1.  Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function.

Authors:  Simon Correa; Marc P Bonaca; Benjamin M Scirica; Sabina A Murphy; Erica L Goodrich; David A Morrow; Michelle L O'Donoghue
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

Review 2.  New insights into modulation of thrombin formation.

Authors:  Henri M H Spronk; Julian I Borissoff; Hugo ten Cate
Journal:  Curr Atheroscler Rep       Date:  2013-11       Impact factor: 5.113

3.  A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice.

Authors:  Yoshiyuki Morishima; Yuko Honda
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

4.  Direct factor Xa inhibition attenuates acute lung injury progression via modulation of the PAR-2/NF-κB signaling pathway.

Authors:  Meng Shi; Linlin Wang; Jian Zhou; Shimeng Ji; Ningfang Wang; Lin Tong; Jing Bi; Yuanlin Song; Jie Hu; Xiaofeng Chen
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

5.  VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice.

Authors:  Alexander S Savchenko; Julian I Borissoff; Kimberly Martinod; Simon F De Meyer; Maureen Gallant; Luise Erpenbeck; Alexander Brill; Yanming Wang; Denisa D Wagner
Journal:  Blood       Date:  2013-11-07       Impact factor: 22.113

Review 6.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

7.  Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs.

Authors:  Özgün Babur; Alexander R Melrose; Jennifer M Cunliffe; John Klimek; Jiaqing Pang; Anna-Liisa I Sepp; Jevgenia Zilberman-Rudenko; Samuel Tassi Yunga; Tony Zheng; Iván Parra-Izquierdo; Jessica Minnier; Owen J T McCarty; Emek Demir; Ashok P Reddy; Phillip A Wilmarth; Larry L David; Joseph E Aslan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

Review 8.  Platelets and von Willebrand factor in atherogenesis.

Authors:  Melinda D Wu; Tamara M Atkinson; Jonathan R Lindner
Journal:  Blood       Date:  2017-02-07       Impact factor: 22.113

Review 9.  Vascular disease and dementias: paradigm shifts to drive research in new directions.

Authors:  Mitchel A Kling; John Q Trojanowski; David A Wolk; Virginia M Y Lee; Steven E Arnold
Journal:  Alzheimers Dement       Date:  2012-11-22       Impact factor: 21.566

10.  Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.

Authors:  H M H Spronk; T Padro; J E Siland; J H Prochaska; J Winters; A C van der Wal; J J Posthuma; G Lowe; E d'Alessandro; P Wenzel; D M Coenen; P H Reitsma; W Ruf; R H van Gorp; R R Koenen; T Vajen; N A Alshaikh; A S Wolberg; F L Macrae; N Asquith; J Heemskerk; A Heinzmann; M Moorlag; N Mackman; P van der Meijden; J C M Meijers; M Heestermans; T Renné; S Dólleman; W Chayouâ; R A S Ariëns; C C Baaten; M Nagy; A Kuliopulos; J J Posma; P Harrison; M J Vries; H J G M Crijns; E A M P Dudink; H R Buller; Y M C Henskens; A Själander; S Zwaveling; O Erküner; J W Eikelboom; A Gulpen; F E C M Peeters; J Douxfils; R H Olie; T Baglin; A Leader; U Schotten; B Scaf; H M M van Beusekom; L O Mosnier; L van der Vorm; P Declerck; M Visser; D W J Dippel; V J Strijbis; K Pertiwi; A J Ten Cate-Hoek; H Ten Cate
Journal:  Thromb Haemost       Date:  2018-01-29       Impact factor: 5.249
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.